A new study co-authored by LIU Pharmacy faculty members Dr. Diren Beyoglu and Dr. Jeff Idle yielded groundbreaking discoveries in cancer epigenetics that could offer new therapeutic treatments for acute myeloid leukemia (AML). The recent findings unveil additional ways altered cancer epigenetics can drive cancer cell proliferation and provides important insights on AML etiology that can also be applied to other cancer types. The research was published in the highly cited Cancers journal of oncology.
